Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. [electronic resource]
Producer: 20160427Description: 111-117 p. digitalISSN:- 1879-355X
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Biomarkers
- Brachytherapy -- methods
- Carcinoma, Squamous Cell -- blood supply
- Cell Hypoxia
- Chemoradiotherapy -- methods
- Cisplatin -- administration & dosage
- Drug Administration Schedule
- Early Termination of Clinical Trials
- Female
- Follow-Up Studies
- Humans
- Niacinamide -- administration & dosage
- Oxygen -- metabolism
- Partial Pressure
- Phenylurea Compounds -- administration & dosage
- Radiation Tolerance -- drug effects
- Sorafenib
- Time Factors
- Tumor Burden
- Uterine Cervical Neoplasms -- blood supply
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.